🇺🇸 FDA
Patent

US 10995146

Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10995146 (Methods of treating severe insulin resistance by interfering with glucagon receptor signaling) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545